CONTRIBUTORS

Neurocritical Care p. 1251-1255 October 2015, Vol.21, No.5 doi: 10.1212/01.CON.0000472607.99016.01
CONTRIBUTORS
BROWSE ARTICLES

Alejandro A. Rabinstein, MD, FAAN, Guest Editor

Professor of Neurology, Mayo Clinic, Rochester, Minnesota

a Dr Rabinstein receives royalties from Elsevier, Oxford University Press, and UpToDate, Inc.

b Dr Rabinstein reports no disclosure.

Katharina Maria Busl, MD, MS

Assistant Professor, Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois

a Dr Busl receives personal compensation as a consultant for Guidepoint Global, LLC.

b Dr Busl reports no disclosure.

W. David Freeman, MD, FSNS, FAAN

Professor of Neurology, Neurosciences Intensive Care Unit Director, Mayo Clinic, Jacksonville, Florida

a Dr Freeman receives book royalties from Cambridge University Press and Oxford University Press.

b Dr Freeman reports no disclosure.

Jennifer E. Fugate, DO

Assistant Professor of Neurology, Divisions of Critical Care Neurology and Cerebrovascular Diseases, Mayo Clinic, Rochester, Minnesota

a,b Dr Fugate reports no disclosures.

David M. Greer, MD, MA, FCCM, FAHA, FNCS, FAAN, FANA

Professor of Neurology, Vice Chair of Neurology, Yale School of Medicine, New Haven, Connecticut

a Dr Greer has served as a consultant for C. R. Bard, Inc.

b Dr Greer reports no disclosure.

Sara E. Hocker, MD

Assistant Professor of Neurology, Mayo Clinic, Rochester, Minnesota

a Dr Hocker has received personal compensation for travel and accommodation expenses from the London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures, and Dr Hocker’s institution receives compensation for her work as a consultant on the data and safety monitoring board of SAGE Therapeutics.

b Dr Hocker discusses the unlabeled/investigational use of lacosamide, levetiracetam, midazolam, propofol, and valproate sodium for the treatment of status epilepticus.

Jessica D. Lee, MD, FAAN

Associate Professor of Neurology, Medical Director, Comprehensive Stroke Program, University of Kentucky College of Medicine, Lexington, Kentucky

a,b Dr Lee reports no disclosures.

Andrew M. Naidech, MD, MSPH, FANA

Associate Professor, Medical Director of Neuro/Spine Intensive Care Unit, Northwestern University Feinberg School of Medicine, Chicago, Illinois

a Dr Naidech reports no disclosure.

b Dr Naidech discusses the unlabeled/investigational use of desmopressin for the treatment of acute intracerebral hemorrhage.

Marc R. Nuwer, MD, PhD, FAAN

Professor of Neurology, Vice Chair of Neurology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California

a Dr Nuwer serves on the board of directors of CortiCare and receives personal compensation as laboratory medical director of SleepMed, Inc.

b Dr Nuwer reports no disclosure.

Adrian M. Owen, PhD

Canada Excellence Research Chair in Cognitive Neuroscience and Imaging, Professor, Department of Psychology, University of Western Ontario, London, Ontario, Canada

a,b Dr Owen reports no disclosures.

Richard R. Sharp, PhD

Director of Biomedical Ethics Research Program, Professor of Biomedical Ethics and Medicine, Mayo Clinic, Rochester, Minnesota

a,b Dr Sharp reports no disclosures.

Kevin N. Sheth, MD, FAHA, FCCM, FNCS, FAAN, FANA

Associate Professor, Chief of Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Yale School of Medicine, New Haven, Connecticut

a Dr Sheth serves on the advisory board of Novartis AG and receives personal compensation as a consultant from C3O Telemedicine and for expert testimony related to acute brain injury. Dr Sheth receives funding from the American Heart Association for research related to nanoparticle delivery of novel stroke agents, and his institution receives a research grant from Remedy Pharmaceuticals, Inc, for a phase 2 study to prevent brain swelling in large stroke.

b Dr Sheth reports no disclosure.

Erik K. St. Louis, MD, FAAN

Associate Professor of Neurology, Mayo Clinic, Rochester, Minnesota

a Dr St. Louis receives personal compensation for serving on the data and safety monitoring board of Inspire, Inc.

b Dr St. Louis reports no disclosure.

Jose I. Suarez, MD, FNCS, FANA

Professor of Neurology, Baylor College of Medicine, Houston, Texas; Head of Vascular Neurology and Neurocritical Care, Baylor St. Luke’s Medical Center, Houston, Texas

a,b Dr Suarez reports no disclosures.

Paul M. Vespa, MD, FAAN

Professor and Director of Neurocritical Care, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California

a,b Dr Vespa reports no disclosures.

Eelco F. M. Wijdicks, MD, PhD, FAAN

Professor of Neurology, College of Medicine, Mayo Clinic, Rochester, Minnesota

a,b Dr Wijdicks reports no disclosures.

G. Bryan Young, MD, FRCPC

Emeritus Professor, Departments of Clinical Neurological Sciences and Medicine, University of Western Ontario, London, Ontario, Canada

a Dr Young receives travel and accommodation expenses as well as personal compensation as a consultant from GE Healthcare and receives royalties from McGraw-Hill Education.

b Dr Young reports no disclosure.

Eduardo E. Benarroch, MD, FAAN

Professor of Neurology, Mayo Clinic, Rochester, Minnesota

a,b Dr Benarroch reports no disclosures.

Adam G. Kelly, MD

Assistant Professor of Neurology, University of Rochester Medical Center, Rochester, New York; Chief of Neurology, Highland Hospital, Rochester, New York

a Dr Kelly has received research support from the Donald W. Reynolds Foundation.

b Dr Kelly reports no disclosure.

© 2015 American Academy of Neurology